Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer

PD-L1 and VISTA are important checkpoint control stations and play an immunomodulatory role in patients with non-small-cell lung cancer. The expression levels of PD-L1 and VISTA between pre- and post-treatment tumor tissue were compared. While PD-L1 expression was >1% in 35% of patients before ne...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 14; no. 14; pp. 1121 - 1131
Main Authors Akdoğan, Orhun, Sütcüoğlu, Osman, Öğüt, Betül, Akyürek, Nalan, Özdemir, Nuriye, Özet, Ahmet, Yazıcı, Ozan
Format Journal Article
LanguageEnglish
Published Future Medicine Ltd 01.10.2022
Subjects
biomarker
chemotherapy
immunotherapy
molecular oncology
PD-L1
radiotherapy
VISTA
Online AccessGet full text

Cover

More Information
Summary:PD-L1 and VISTA are important checkpoint control stations and play an immunomodulatory role in patients with non-small-cell lung cancer. The expression levels of PD-L1 and VISTA between pre- and post-treatment tumor tissue were compared. While PD-L1 expression was >1% in 35% of patients before neoadjuvant therapy, PD-L1 expression was >1% in 65% of patients after treatment (p = 0.004). VISTA expression was >1% in 41% of patients before treatment, and this rate was 65% after treatment (p = 0.025). Chemotherapy and chemoradiotherapy can be used as immunizers by increasing PD-L1 and VISTA expression levels.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2021-0338